LSL Pharma Group Announces Closing of Second and Final Tranche of Private Placement and Closing of Units for Debt
2024年7月15日 - 8:00PM
LSL PHARMA GROUP INC. (TSXV: LSL) (the
"
Corporation" or "
LSL Pharma "),
a Canadian integrated pharmaceutical company, is pleased to
announce that it closed on July 12, 2024, the second and last
tranche of a non-brokered private placement (the
“
Financing”) consisting of 2,400,000 units (each,
a “
Unit”) at a price of $0.40 per Unit for total
gross proceeds of $960,000. Each Unit consists of one class A share
of the Corporation (a “
Common Share”) and one
Common Share purchase warrant (a “
Warrant”). Each
Warrant entitles the holder, subject to adjustments in certain
cases, to purchase one Common Share (a “
Warrant
Share”) at a price of $0.70 for a period of 24 months
following the closing date.
The Corporation was thus able to raise with both
tranches a total of $2,450,800 in Financing. The cash proceeds of
the Financing will be used to further expand production capacity at
each of the LSL Laboratories, Steri-Med Pharma, and Virage Santé
plants and for general working capital purposes.
In connection with this second and final tranche
of the Financing, the Corporation paid to finders dealing at arm’s
length with the Corporation, finders’ fees for a total of $14,600
in cash and issued 36,500 finders’ warrants (“Finder’s
Warrants”). Each Finder’s Warrant entitles the holder to
purchase one (1) Common Share at a price of $0.70 for a period of
18 months following the closing date.
Further to its press release of June 5, 2024,
the Corporation also announces that it has completed the settlement
of $560,082.88 of the Corporation’s debts through the issuance of
1,400,206 Units (the “Units for Debt”). The debts
converted into Units relate to promissory notes and non-convertible
secured debentures. The Corporation had elected to settle such
debts through the issuance of Units to preserve cash and strengthen
the Corporation’s balance sheet.
“This latest tranche of our private Financing,
including the conversion of debt into equity, further confirms
investors' continued interest in LSL Pharma. This new financing
will enable us to maintain and accelerate our organic growth
initiatives for our three manufacturing sites, and to fund the
growth of our ophthalmic product portfolio," said François Roberge,
President and CEO of the Corporation. "Finally, since the beginning
of our 2024 fiscal year, we have successfully completed a series of
financial transactions aimed at strengthening our financial
position and reducing our debt. We intend to continue pursuing
similar opportunities over the coming quarters," added Mr.
Roberge.
Each issued Unit, Common Share, Warrant, Warrant
Share, Finder’s Warrant and Common Share issued upon the exercise
of the Finder’s Warrant will be subject to a four-month hold period
under the applicable securities laws. The Financing and the Units
for Debt are subject to the receipt of all necessary regulatory
approvals, including the final approval of the TSX Venture
Exchange.
CAUTION REGARDING FORWARD-LOOKING
STATEMENTS
This press release may contain forward-looking
statements as defined under applicable Canadian securities
legislation. Forward-looking statements can generally be identified
by the use of forward-looking terminology such as "may", "will",
"expect", "intend", "estimate", "continue" or similar expressions.
Forward-looking statements are based on a number of assumptions and
are subject to various known and unknown risks and uncertainties,
many of which are beyond the Corporation's ability to control or
predict, that could cause actual results or performance to differ
materially from those expressed or implied in such forward-looking
statements. These risks and uncertainties include, but are not
limited to, those identified in the Corporation's filings with
Canadian securities regulatory authorities, such as legislative or
regulatory developments, increased competition, technological
change and general economic conditions. All forward-looking
statements made herein should be read in conjunction with such
documents.
Readers are cautioned not to place undue
reliance on forward-looking statements. No assurance can be given
that any of the events referred to in the forward-looking
statements will transpire, and if any of them do, the actual
results, performance or achievements of the Corporation may differ
materially from those expressed or implied by the forward-looking
statements. All forward-looking statements contained in this press
release speak only as of the date of this press release. The
Corporation does not undertake to update these forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
ABOUT LSL PHARMA GROUP INC.
LSL Pharma Group Inc. is an integrated Canadian
pharmaceutical company specializing in the development,
manufacturing, and commercialization of high-quality sterile
ophthalmic pharmaceuticals, as well as natural health products in
solid and liquid dosage forms. For further information, please
visit the following website www.groupelslpharma.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
CONTACT
François Roberge
President and Chief Executive Officer
(514) 664-7700
E-mail: Investors@groupelslpharma.com
OR
Luc Mainville
Executive VP & Chief Financial Officer
(514) 664-7700 ext.: 301
E-mail : lmainville@groupelslpharma.com
LSL Pharma (TSXV:LSL)
過去 株価チャート
から 7 2024 まで 8 2024
LSL Pharma (TSXV:LSL)
過去 株価チャート
から 8 2023 まで 8 2024